. Author manuscript; available in PMC: 2010 Jan 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2009 Jan;15(1):1–11. doi: 10.1016/j.bbmt.2008.10.026

Table 2.

T cell, B cell, and granulocyte engraftment in blood in B6 mArt^-/- mice following congenic and allogeneic transplants.

BMT	Marrow Prep and Pre-condition	1 Month Post-HSCT		2 Months Post-HSCT		At least 3 Months Post-HSCT
BMT	Marrow Prep and Pre-condition	T cells, %^*	B cells, %^*	T cells, %^*	B cells, %^*	T cells, %^*	B cells, %^*	Granulocytes, %^†
Congenic (CD45.1)	HSC^‡ (n=6)	4.0±2.7	0	16.3±4.1	0	64.4±8.2	0	N/A
Congenic (CD45.1)	HSC^‡/TBI (n=4)	44.6±3.5	18.4±2.8	56.6±4.5	23.5±7.0	46.1±2.2	35.2±2.1	64.1±11.2
Allogeneic (BALB/c)	HSC^‡ (n=5)	0	0	0	0	not available	not available	not available
Allogeneic (BALB/c)	HSC^‡/TBI (n=4)	1.8±1.2(3)^£	3.3±1.5(3)^£	4.4±3.4(2)^£	3.4±0.7(2)^£	not available	not available	not available

WT mice used as controls had a mean percent of 28.5±17.7 CD3⁺ (T cells) and a mean percent of 37.5 ± 2.1 CD45R/B220⁺ (B cells) in the CD45⁺ lymphocyte gate.

Mean percent of CD3⁺ (T cells) or CD45R/B220⁺ (B cells) in CD45⁺ lymphocyte gate ± standard deviation.

^†

Mean percent of donor granulocytes of total granulocytes ± standard deviation.

^‡

For HSC (lin⁻c-kit⁺), 1 × 10⁵ cells were injected. Mice treated with TBI (Total Body Irradiation) received 3Gy.

^£

Mean±SD of engrafted animals. ( ) = the number of transplanted mice that engrafted (≥0.75% donor cells).